{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:59:16Z","timestamp":1790168356746,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106886","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:52:56Z","timestamp":1785253976000},"page":"106886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disseminated intravascular coagulation in chimeric antigen receptor T-cell therapy: a 6-year nationwide analysis of clinical outcomes and health care resource utilization in patients with hematologic malignancies"],"prefix":"10.1016","volume":"10","author":[{"given":"Adamsegd Isac","family":"Gebremedhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-0281","authenticated-orcid":false,"given":"Samhitha","family":"Gundakaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semere","family":"Tesfamariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reesha","family":"Bodiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh","family":"Souleymane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106886_bib1","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2021-152465","article-title":"Coagulopathy following chimeric antigen receptor T cell therapy in R\/R adult B cell malignancies: a single center experience","volume":"138","author":"Belbachir","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106886_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3233\/THC-220537","article-title":"The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: a systematic review and meta-analysis","volume":"31","author":"Xia","year":"2023","journal-title":"Technol Health Care"},{"key":"10.1016\/j.rpth.2026.106886_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/atm-22-3814","article-title":"The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study","volume":"10","author":"Dong","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.rpth.2026.106886_bib4","article-title":"CAR T-cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2026.106886_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.rpth.2026.106886_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hon.3155","article-title":"A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2","volume":"41","author":"Liu","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.rpth.2026.106886_bib7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/CM9.0000000000002288","article-title":"Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy","volume":"135","author":"Mei","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.rpth.2026.106886_bib8","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106886_bib9","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106886_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098349","article-title":"Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies","volume":"24","author":"Schorr","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2026.106886_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13613-023-01216-8","article-title":"Disseminated intravascular coagulation is strongly associated with severe acute kidney injury in patients with septic shock","volume":"13","author":"Helms","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.rpth.2026.106886_bib12","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2147\/IDR.S218592","article-title":"Coagulative biomarkers on admission to the ICU predict acute kidney injury and mortality in patients with septic shock caused by intra-abdominal infection","volume":"12","author":"Xu","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.rpth.2026.106886_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1177\/08850666241253537","article-title":"Epidemiology and outcomes of hospitalized chimeric antigen receptor T-cell (CAR-T) therapy patients who developed acute respiratory failure","volume":"39","author":"Kurtz","year":"2024","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rpth.2026.106886_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1434231","article-title":"CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023)","volume":"15","author":"Shi","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rpth.2026.106886_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.thromres.2020.03.023","article-title":"The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome","volume":"191","author":"Gando","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106886_bib16","article-title":"Disseminated intravascular coagulation associated organ failure in obstetric patients admitted to intensive care units: a multicenter study in China","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2026.106886_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106886_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rpth.2026.106886_bib19","first-page":"CD011305","article-title":"Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support","volume":"5","author":"Radford","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2026.106886_bib20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106886_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","article-title":"Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities","volume":"33","author":"Dholaria","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.rpth.2026.106886_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106886_bib23","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/ijms21113886","article-title":"A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity","volume":"21","author":"Gavriilaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2026.106886_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0030-1254048","article-title":"Disseminated intravascular coagulation in hematologic malignancies","volume":"36","author":"Franchini","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106886_bib25","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","article-title":"Costs and impact of disease in adults with sickle cell disease: a pilot study","volume":"8","author":"Lanzkron","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106886_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278950","article-title":"Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: results from a comprehensive cancer center","volume":"17","author":"Chacim","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.106886_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106886_bib28","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106886_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2026.106886_bib30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106886_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.rpth.2026.106886_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1055\/a-2453-7920","article-title":"Validity of diagnosis of disseminated intravascular coagulation based on International Classification of Diseases coding in a claims database","volume":"125","author":"Umemura","year":"2025","journal-title":"Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:59:15Z","timestamp":1790164755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035442"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106886","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disseminated intravascular coagulation in chimeric antigen receptor T-cell therapy: a 6-year nationwide analysis of clinical outcomes and health care resource utilization in patients with hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106886"}}